Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia

Article Page

Abstract

Therapeutic options for relapsed/refractory B-cell acute lymphoblastic leukemia have evolved in the past few years. The FDA has approved three novel therapies for this disease: inotuzumab ozogamicin (an anti-CD22 antibody–drug conjugate), blinatumomab (a bispecific T-cell engager), and chimeric antigen receptor T-cell therapy. Although these novel immunotherapies have revolutionized the therapeutic landscape, it is important to understand the crucial aspects of administration, especially toxicity. In this article, we review the unique toxicities and adverse effects of blinatumomab and inotuzumab ozogamicin and provide recommendations for prevention of adverse effects as well as the management options for each medication.

Keywords: acute lymphoblastic leukemia, immunotherapy, blinatumomab, inotuzumab, side effects.

Citation: Conde-Royo D, Juárez-Salcedo LM, Dalia S. Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia. Drugs in Context 2020; 9: 2020-7-2. DOI: 10.7573/dic.2020-7-2

Contributions: Diego Conde-Royo and Luis Miguel Juárez-Salcedo contributed equally to this manuscript. Luis Miguel Juárez-Salcedo and Samir Dalia should be considered joint corresponding authors. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/09/dic.2020-7-2-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2020 Conde-Royo D, Juárez-Salcedo LM, Dalia S. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Conde-Royo D, Juárez-Salcedo LM, Dalia S. https://doi.org/10.7573/dic.2020-7-2. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/management-of-adverse-effects-of-new-monoclonal-antibody-treatments-in-acute-lymphoblastic-leukemia

Correspondence: Luis Miguel Juárez-Salcedo, Hematology Department, Gregorio Marañón University Hospital, Madrid, Spain. dr.luisjuarez@gmail.com

Provenance: Invited; externally peer reviewed.

Submitted: 3 July 2020; Peer review comments to author: 8 July 2020; Revised manuscript received: 15 September 2020; Accepted: 16 September 2020; Publication date: 14 October 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF